Szot Patricia, White Sylvia S, Greenup J Lynne, Leverenz James B, Peskind Elaine R, Raskind Murray A
Northwest Network for Mental Illness Research, Education, and Clinical Center, Veterans Administration Puget Sound Health Care System, Seattle, Washington 98108, USA.
J Neurosci. 2006 Jan 11;26(2):467-78. doi: 10.1523/JNEUROSCI.4265-05.2006.
In Alzheimer's disease (AD), there is a significant loss of locus ceruleus (LC) noradrenergic neurons. However, functional and anatomical evidence indicates that the remaining noradrenergic neurons may be compensating for the loss. Because the noradrenergic system plays an important role in learning and memory, it is important to determine whether compensation occurs in noradrenergic neurons in the LC and hippocampus of subjects with AD or a related dementing disorder, dementia with Lewy bodies (DLB). We observed profound neuronal loss in the LC in AD and DLB subjects with three major changes in the noradrenergic system consistent with compensation: (1) an increase in tyrosine hydroxylase (TH) mRNA expression in the remaining neurons; (2) sprouting of dendrites into peri-LC dendritic zone, as determined by alpha2-adrenoreceptors (ARs) and norepinephrine transporter binding sites; and (3) sprouting of axonal projections to the hippocampus as determined by alpha2-ARs. In AD and DLB subjects, the postsynaptic alpha1-ARs were normal to elevated. Expression of alpha1A- and alpha2A-AR mRNA in the hippocampus of AD and DLB subjects were not altered, but expression of alpha1D- and alpha2C-AR mRNA was significantly reduced in the hippocampus of AD and DLB subjects. Therefore, in AD and DLB subjects, there is compensation occurring in the remaining noradrenergic neurons, but there does appear to be a loss of specific AR in the hippocampus. Because changes in these noradrenergic markers in AD versus DLB subjects were similar (except neuronal loss and the increase in TH mRNA were somewhat greater in DLB subjects), the presence of Lewy bodies in addition to plaques and tangles in DLB subjects does not appear to further affect the noradrenergic compensatory changes.
在阿尔茨海默病(AD)中,蓝斑(LC)去甲肾上腺素能神经元大量丧失。然而,功能和解剖学证据表明,剩余的去甲肾上腺素能神经元可能在代偿这种损失。由于去甲肾上腺素能系统在学习和记忆中起重要作用,因此确定AD或相关痴呆症(路易体痴呆,DLB)患者的LC和海马中的去甲肾上腺素能神经元是否发生代偿至关重要。我们观察到AD和DLB患者的LC中存在严重的神经元丧失,同时去甲肾上腺素能系统有三个与代偿一致的主要变化:(1)剩余神经元中酪氨酸羟化酶(TH)mRNA表达增加;(2)由α2-肾上腺素能受体(ARs)和去甲肾上腺素转运体结合位点确定,树突向LC周围树突区发芽;(3)由α2-ARs确定,轴突向海马投射发芽。在AD和DLB患者中,突触后α1-ARs正常至升高。AD和DLB患者海马中α1A-和α2A-AR mRNA的表达未改变,但AD和DLB患者海马中α1D-和α2C-AR mRNA的表达显著降低。因此,在AD和DLB患者中,剩余的去甲肾上腺素能神经元发生了代偿,但海马中确实出现了特定AR的丧失。由于AD与DLB患者中这些去甲肾上腺素能标志物的变化相似(除了神经元丧失以及DLB患者中TH mRNA的增加稍大),DLB患者中除了斑块和缠结外还存在路易小体,这似乎并未进一步影响去甲肾上腺素能的代偿变化。